Astellas, FibroGen hit primary endpoint in PhIII; vTv inks PDE4 inhibitor deal with Newsoara
→ Astellas and FibroGen are reporting that their fourth late-stage study of roxadustat hit the primary endpoint for anemia in patients with CKD. …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
